Efficacy of BRAF‐Inhibitor Therapy in BRAF(V600E)‐Mutated Adult Langerhans Cell Histiocytosis

Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm. To date, there is a lack of U.S. Food and Drug Administration–approved treatments in adult LCH to establish optimal first‐line therapy. We conducted a retrospective, single‐center case series evaluating the use of BRAF inhibitors in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Hazim, Antonious Z., Ruan, Gordon J., Ravindran, Aishwarya, Abeykoon, Jithma P., Scheckel, Caleb, Vassallo, Robert, Ryu, Jay H., Tobin, W. Oliver, Koster, Matthew J., Bennani, N. Nora, Rech, Karen L., Young, Jason R., Shah, Mithun V., Goyal, Gaurav, Go, Ronald S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2020
Soggetti:
Commentary
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7938396/
https://ncbi.nlm.nih.gov/pubmed/32985015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13541
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi